Nov 30, 2020 2:47pm EST HIV-Like Virus Eliminated from the Genomes of Primates; Excision BioTherapeutics Advancing the Innovation to Clinical Development
Nov 03, 2020 9:00am EST CRISPR-Focused Excision BioTherapeutics Announces Business Advisory Board and Addition of Interim Chief Business Officer
Aug 04, 2020 12:00pm EDT Excision BioTherapeutics Appoints Veteran Genome Editing Expert TJ Cradick, PhD as Chief Scientific Officer
Mar 11, 2020 3:27pm EDT Excision BioTherapeutics Announces Data Presentation at CROI from IND-Enabling Non-Human Primate studies of EBT-001, supporting a CRISPR Gene Editing Technology for HIV Elimination
Dec 03, 2019 12:30pm EST CRISPR-focused Excision BioTherapeutics Strengthens Board of Directors Appointing Veteran Pharmaceutical Executive Bill Carson, M.D.
Nov 21, 2019 12:00pm EST Excision BioTherapeutics Presents Data to Support HIV Cure Using CRISPR Gene Editing Technology
Nov 18, 2019 12:00pm EST CRISPR Gene Editing Eliminates Herpes Simplex Virus and JC Virus, Demonstrating Feasibility of a Potential Functional Cure
Jul 02, 2019 11:16am EDT HIV Eliminated from the Genomes of Living Animals; Excision BioTherapeutics Advancing the Innovation to Clinical Development
Nov 13, 2017 10:01am EST Excision BioTherapeutics Exclusively Licenses New CRISPR-Cas Gene Editors from UC Berkeley, to be Used for Viral Infections
Sep 06, 2017 10:00am EDT HIV Cure-Focused Excision BioTherapeutics Secures $10 Million in Seed Funding Led by ARTIS Ventures